Publications hub
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advisory bodies and committees (369)
- Scheduling (national classification system) (160)
- Prescription medicines (37)
- Advertising (25)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (24)
- Therapeutic goods regulation (21)
- Medical devices safety (16)
- Manufacturing (11)
- Safety (11)
- Non-prescription medicines (10)
- Complementary medicines (9)
- Regulatory compliance (9)
- Over the counter (OTC) medicines (8)
- COVID-19 vaccines (7)
- Listed medicines (7)
- Registered complementary medicines (7)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Assessed listed medicines (5)
- Fees and payments (4)
- Shortages (4)
- Sunscreens (4)
- Alert/Advisory (3)
- Clinical trials (3)
- Legislation (3)
- Compliance and enforcement hub (2)
- Import and export (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
727 result(s) found, displaying 1 to 25
-
Meeting statementsThe 85th meeting of the Advisory Committee on Medical Devices (ACMD) was held on 12 June 2025.
-
PublicationsBased on the data considered in this safety review, we recommend regulatory controls for homosalate and oxybenzone to restrict their permitted concentrations and use in therapeutic sunscreens.
-
PublicationsThis updated safety review uses the Australian Sunscreen Exposure Model to assess the risk of benzophenone as a degradant in sunscreens.
-
PublicationsThis Cost Recovery Implementation Statement (CRIS) 2025-2026 provides information on how we implement, and cost recover our regulatory activities.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 27 July 2025
-
Scheduling decisions (interim)Find out about the public submissions on scheduling matters referred to the ACMS #46 meeting held in November 2024
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
PublicationsThe report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Meeting statementsCommunique from the 8th meeting of the WHPWG 30 October 2024
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 52
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulation 42ZCZS and regulation 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Meeting statementsCommunique from the 2nd meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 1 May 2025
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 meeting held in June 2025
-
Meeting statementsMeeting statement from the 16th Consumer Working Group meeting that took place on 25 March 2025.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsRead the meeting statement from the meeting of the Advisory Committee on Medical Devices.
-
Scheduling submissionsFind out about the public submissions on scheduling matters referred to the ACMS #47 and Joint ACMS-ACCS #40 meetings held in June 2025
-
PublicationsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Meeting statementsCommunique from the meeting of the TGACC
-
PublicationsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Meeting statementsRead the meeting statement from 13 February 2025 meeting of the Advisory Committee on Medical Devices.
-
PublicationsDetailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.
-
PublicationsThis report provides information about our regulatory performance for the 2023-24 financial year.
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 4 April 2025